Establishment Labs (NASDAQ:ESTA) Stock Rating Lowered by Wall Street Zen

Key Points

• Establishment Labs has been downgraded from a "hold" to a "sell" rating by Wall Street Zen, indicating a bearish outlook on the stock's future performance.
• Despite the downgrade, the company maintains a consensus rating of "Moderate Buy" with several analysts setting target prices, including $70.00 from Mizuho and $60.00 from Canaccord Genuity.
• Establishment Labs reported earnings of ($0.57) per share, missing analyst estimates, though revenue showed a year-over-year increase of 16.1%.

Establishment Labs (NASDAQ:ESTA - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday.

Several other equities research analysts also recently weighed in on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Establishment Labs in a research note on Wednesday. Citigroup restated a "neutral" rating on shares of Establishment Labs in a research note on Tuesday. Needham & Company LLC reiterated a "buy" rating and set a $48.00 price objective on shares of Establishment Labs in a research note on Friday, June 13th. Canaccord Genuity Group assumed coverage on shares of Establishment Labs in a research note on Wednesday, August 20th. They set a "buy" rating and a $60.00 price objective for the company. Finally, Mizuho lifted their price objective on shares of Establishment Labs from $58.00 to $70.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 16th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Establishment Labs currently has a consensus rating of "Moderate Buy" and a consensus target price of $56.50.

Establishment Labs Price Performance

Shares of ESTA opened at $38.94 on Friday. The company has a market cap of $1.13 billion, a price-to-earnings ratio of -12.77 and a beta of 0.85. Establishment Labs has a twelve month low of $26.56 and a twelve month high of $50.85. The company has a quick ratio of 1.67, a current ratio of 2.84 and a debt-to-equity ratio of 9.71. The company has a 50 day moving average of $39.61 and a two-hundred day moving average of $38.04.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.03). The firm had revenue of $51.30 million during the quarter, compared to analyst estimates of $50.80 million. Establishment Labs had a negative net margin of 49.89% and a negative return on equity of 224.34%. Establishment Labs's revenue was up 16.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.62) earnings per share. Establishment Labs has set its FY 2025 guidance at EPS. As a group, analysts predict that Establishment Labs will post -2.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Guided Capital Wealth Management LLC lifted its position in Establishment Labs by 3.8% during the third quarter. Guided Capital Wealth Management LLC now owns 51,650 shares of the company's stock valued at $2,117,000 after purchasing an additional 1,908 shares during the period. Patriot Financial Group Insurance Agency LLC lifted its position in Establishment Labs by 5.8% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 6,375 shares of the company's stock valued at $261,000 after purchasing an additional 350 shares during the period. Osaic Holdings Inc. lifted its position in Establishment Labs by 900.0% during the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company's stock valued at $85,000 after purchasing an additional 1,800 shares during the period. Soleus Capital Management L.P. acquired a new position in Establishment Labs during the second quarter valued at $9,050,000. Finally, GMT Capital Corp acquired a new position in Establishment Labs during the second quarter valued at $4,218,000. 72.91% of the stock is currently owned by institutional investors and hedge funds.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.